BNTX - BioNTech SE

95.03
0.890   0.937%

Share volume: 765,939
Last Updated: 12-24-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: -0.02%

PREVIOUS CLOSE
CHG
CHG%
$94.14
0.89
0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
9%
Profitability 0%
Dept financing 12%
Liquidity 74%
Performance 0%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
3.10%
1 Month
-7.47%
3 Months
-3.11%
6 Months
-10.47%
1 Year
-16.47%
2 Year
-9.26%
Key data
Stock price
$95.03
P/E Ratio 
-40.47
DAY RANGE
$94.69 - $96.18
EPS 
-$0.45
52 WEEK RANGE
$81.20 - $129.27
52 WEEK CHANGE
-$16.60
MARKET CAP 
20.976 B
YIELD 
N/A
SHARES OUTSTANDING 
237.766 M
DIVIDEND
$2.1322
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-04-2025
BETA 
1.04
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,783,267
AVERAGE 30 VOLUME 
$1,582,927
Company detail
CEO: Ugur Sahin
Region: US
Website: biontech.de
Employees: 3,080
IPO year: 2019
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

BioNTech SE develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma. It also develops neoantigen specific immunotherapy, such as Autogene cevumeran (BNT122) and BNT141.

Recent news